Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033610 | 0.79 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL6529631 | 0.79 | TRPV1 (0.40) | TRPV1TNNI3KAURKARPS6KB1AURKB | |
| SCHEMBL5820279 | 0.78 | TRPV1 (0.56) | TRPV1TNNI3K | |
| SCHEMBL6529633 | 0.77 | ALDH1A1 (0.42) | TRPV1TNNI3KEGFRAURKARPS6KB1 | |
| SCHEMBL6033061 | 0.77 | TRPV1 (0.50) | TRPV1TNNI3K | |
| SCHEMBL5809165 | 0.76 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL4114663 | 0.76 | EGFR (0.44) | EGFRABL1BCR | |
| SCHEMBL4114668 | 0.76 | EGFR (0.49) | EGFRABL1 | |
| SCHEMBL5801218 | 0.76 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL6478367 | 0.76 | TRPV1 (0.58) | TRPV1AURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | TRPV1 11/4885TNNI3K 2340/4885EGFR 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.